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Hippocampal sparing in brain radiotherapy
Monika Konopka-Filippow1, 2, Ewa Sierko1, 2, 3, Marek Z. Wojtukiewicz1, 3
Radiotherapy is one of the principal methods for treating brain cancer. Over recent years, a decline in patient quality 
of life has increasingly been observed in those undergoing brain irradiation, where hippocampal-dependent cogni-
tive function has become impaired. 
The hippocampus is a paired structure of the limbic system situated in the medial temporal lobes of the telencepha-
lon. Preliminary findings suggest that irradiation damaged neural stem cells in the hippocampus undergo apoptosis, 
resulting in deteriorating cognitive function. 
Despite the technical aspects for affording hippocampal avoidance during irradiation, much controversy still sur-
rounds the techniques that shield the hippocampus without reducing the benefits of the intended radiotherapy for 
a given clinical condition. Furthermore, a tolerated radiation dose sufficient for preserving neural stem cell function 
has not been yet established. 
Delivering a method for an unequivocal assessment of cognitive function, post-irradiation, is also fraught with difficulty. 
Hitherto, only subjective psychological testing have been applied such as MMSE, HVLT or AVLT methods. Objective 
methods for optimally determining radiation-induced injury to the hippocampal region are still being investigated.
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Key words: hippocampal sparing, brain radiotherapy, cognitive function
Introduction
Brain tumours constitute a considerable clinical prob-
lem because they affect this vital organ of the human body 
and where choosing an effective and safe treatment poses 
many challenges. During recent decades, morbidity rates 
for primary brain tumours in Poland have increased with 
around 3000 cases now reported annually. This represents 
2% of all cancers for both genders and the average age at 
diagnosis is between 50 and 60 years. Brain metastases (BMs) 
are twice more likely to occur than primary brain tumours, 
at rates of around 15%–20% in all those adult patients with 
cancers of varying origin. In children however, cases of BM 
account for only 0.5% of all brain cancer [1].
One of the basic methods for treating patients suffering 
brain cancer, both primary and secondary, is by radiotherapy 
(RT). The advantages of using RT over other therapeutic 
methods are, amongst others, the possibility of eliminating 
not only the macroscopically visible tumour, but also the 
micro-foci (eg. in cases of prophylactic cranial irradiation in 
patients with small cell lung cancer), treating patients with 
multiple BMs or anticancer treatment of patients diagnosed 
with inoperable brain tumours. Furthermore, the presence 
of the blood-brain barrier does not compromise the effec-
tiveness of RT, in contrast to those chemotherapeutic agents 
which are insufficiently capable of crossing this barrier. In 
planning brain RT, due consideration must be taken of many 
critical structures, termed ‘Organs at Risk’ (OAR) which are 
especially sensitive/susceptible to ionizing radiation. These 
include, amongst others, lenses, optic nerves and cross-
over junction between the optic nerves and brain stem. 
Advanced RT techniques enable a more improved confocal 
beam radiotherapy directed towards the RT target area, 
whilst sparing critical structures which play special roles 
whenever tumours are located within the brain.
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In patients with primary brain tumours, RT is applied to 
a precisely delineated area restricted to the tumour or the 
tumour bed (+/– swelling of the tissues around the tumour, 
+/– margin of tissue surrounding the tumour). Quite often 
clinical circumstances dictate irradiating an extensive area 
of the brain (eg. in cases of infiltrating high malignant grade 
gliomas) which may lead a deteriorating quality of life for 
patients after treatment. It should however be stressed that 
using combination therapy in patients with brain tumours 
increases the chances of an ever longer survival. An example 
is afforded by patients suffering from glioblastoma multi-
forme (glioblastoma), where the combination of surgical 
treatment with adjuvant chemoradiotherapy improves local 
control (LC) and extends overall survival (OS) [2]. At the same 
time, patients undergoing antineoplastic therapy are more 
likely to suffer from worsening psychomotor dysfunction.
A slightly different situation exists for patients with me-
tastases diagnosed as having just single BMs, in the absence 
of extracranial metastatic disease. In such cases, the risk of 
the brain treatment failing is relatively small which for most 
clinical situations, with suitably small volume metastases, 
makes possible the irradiation of the tumour metastasis by 
using stereotactic techniques of radiotherapy/radiosurgery 
(SRT/SRS) instead of undergoing whole brain RT (i.e. WBRT). 
By such means, the adverse effects of RT are lessened [3]. In 
cancer patients with current BM and extracranial metastases, 
the potential benefits from adding WBRT to SRT neverthe-
less outweigh their adverse effects [4].
Through using WBRT on BM patients the risk of dis-
ease progression in the brain becomes reduced, thereby 
improving patient Quality of Life (QoL) and in some cases 
extending their OS [5–8]. Despite this, there is a loss of 
neurocognitive function post-WBRT that is manifest and 
intensified, the longer the survival time of patients becomes 
[9, 10]. A number of prospective randomised clinical trials 
have demonstrated that WBRT improves LC patients with 
BM [5–7] but that its adoption is associated with declining 
QoL in terms of cognitive function when compared to the 
pre-treatment status [11].
The term ‘cognitive function’ refers to those mental 
processes responsible for information processing which 
inputs from the external environment and is internalised 
in the mind, that enables knowledge acquisition through 
interpreting reality and is essential for normal mental func-
tion. The basic cognitive functions are perception, attention 
and memory, whilst complex ones include thinking and 
imagination [12].
Deficits in cognitive function post-RT of the brain are 
apparent primarily as a short-term memory loss manifested 
as verbal memory dysfunction, problems with learning and 
being able to utilise newly acquired information [13, 14]. The 
process of memorising is closely linked to the functioning 
of granule cells from the hippocampal dentate gyrus [15].
The hippocampus as an organ at risk
The hippocampus is a twinned component of the limbic 
system located in the telencephalon within the tempo-
ral lobes of the cerebral cortex neighbouring the lateral 
ventricles (Fig.1). It plays a key role, inter alia, in learning, 
remembering, creating memories and relaying informa-
tion from short-term to long-term memory together with 
the ability of remembering information [16]. The so-called 
neural stem cells (NSCs) are responsible for such functions 
and are located in the granular zone of the dentate gyrus 
within the hippocampus, which are the only brain cells 
possessing mitotic potential [17]. These cells in adult mam-
mal brains are concentrated around only two niches: the 
subventricular zone (SVZ) of the anterolateral recess and 
the subgranular zone (SGZ) of the dentate gyrus within the 
hippocampus (Fig.1).
Maintaining cellular homeostasis in the hippocampus 
enables NSCs to undergo: proliferation, differentiation, 
normal cell function and apoptosis [18]. A year after birth, 
the numbers of NSCs in the human brain rapidly fall, after 
which, in subsequent years of childhood and adulthood they 
decrease at a more measured pace [19–21]. These cells pro-
liferate in the subgranular zone, and then migrate circumfer-
entially, becoming integrated with mature granular cells of 
the dentate gyrus within the hippocampus, and then mature 
into fully functional nerve cells [22]. In the human adult, NSC 
proliferation assures the formation of around 700 new nerve 
cells daily and that 1.75% of all neurones are replaced by 
new ones [23]. There are reports of NSCs migrating from the 
hippocampus to more remote area of the brain to replace 
damaged astrocytes or oligodendrocytes by transforming 
themselves into the given cell type [24, 25] (Fig.2).
NSCs are sensitive to various injuring factors, such as 
ischemia, stress or ionizing radiation [26]. Indeed, studies 
performed on mice have shown that ionizing radiation in-
duces breakage of double-stranded DNA in NSC precursor 
cells leading to apoptosis [26]. This RT-dependent loss of 
NSCs leads to a deficient cognitive function, especially dis-
orders of learning and memory [27–29]. In studies on young 
rats and mice subjected to brain RT, most of the enhanced 
NSC apoptosis in the hippocampus occurred after 12 hours 
post-RT [28, 30], thus indicating radiation-dependent sup-
pression of neurogenesis in precursor NSCs [27, 31, 32].
It is therefore considered that in patients having under-
gone WBRT, then the observed impairments to learning, 
memory or spatial processing are the result of damage to 
the NSCs from the hippocampal dentate gyrus [33]. Inter-
estingly, Mahajan et al. [34] found that damage to the left 
hippocampus during RT for brain cancer results in impaired 
learning and delayed recall, however there was no such cor-
relation when tumours from the right side were subjected 
to RT [35]. The IQ (Intelligent Quotient) was found to decline 
in patients two years after undergoing conformal SRT (54 
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Gy in 30 fractions), whenever a radiation dose exceeded 
42.5 Gy and was given to more than 13% by volume of the 
left temporal lobe, when compared to the pre-treatment 
status [35].
A study by Monje et al. [36] demonstrated that NSCs 
neurogenesis becomes inhibited by inflammation in the 
hippocampus through damage to the actinic granular zone 
of the dentate gyrus. Subsequent studies by this group con-
ducted on rats revealed that the levels of dose fractionation 
and neurogenesis were correlated; i.e. a single fractional 
dose of 10 Gy induced a 62% decrease in the NSC prolifera-
tion rate whilst reducing the severity of neurogenesis by 
97% within the hippocampal area when compared to the 
effects achieved by a single dose of 5 Gy which, according 
to this study, was found to be the damage limiting dose 
for NSCs [36, 37].
From the radiobiological viewpoint, the effect of ion-
izing radiation on the hippocampus is not completely un-
derstood and remains still debateable. According to the 
QUANTEC study (Quantitative Analysis of Normal Tissue 
Effects in the Clinic), the brain α / β ratio/index is 2.9 [39] 
but this is not explicitly specified for the hippocampus. 
Some investigators take an α / β ratio of between 2 and 3 
for the hippocampus [40], whilst others use a value of 10 
for hippocampal NSCs; the same as for stem cells [41, 42]. 
It is worth emphasising that preclinical experiments have 
demonstrated that doses of even 2 Gy cause apoptosis in 
NSCs [27, 43], thereby reducing the survival of these cells 
by even 50% [44].
Because of the key role that NSCs play (from the hip-
pocampal dentate gyrus) in neurogenesis [45–48], any brain 
irradiation caused losses result in impaired cognitive func-
tion, especially that of memory [27, 49– 53]. In a 18-month 
follow-up study on patients with benign or low-grade 
glioma subjected to SRT, Gondi et al. [44] showed that the 
higher dose of 7.3 Gy (normalised to an equivalent dose of 2 
Gy) applied to at least 40%, by volume, of the hippocampus 
causes damage to the NSCs — resulting in problems with 
memory and learning.
Onset time of cognitive dysfunction, after brain RT
Those patients fortunate to experience long-term sur-
vival (i.e. over 12 months) were found to suffer from late 
side effects after brain RT, especially from the hypofraction-
ated type, which were manifested mainly by dementia and 
psychomotor slowing [54]. Only after 2000, did cognitive 
function begin to be carefully evaluated following brain RT 
through using specialized psychological testing.
A RTOG 0914 study on 445 BM patients undergoing 
WBRT demonstrated that both RT hypofractionation (30Gy/ 
/10fr) as well as conventional RT (40Gy/20fr) lead to 
a significant reduction in cognitive function. Using the ‘Mini 
Mental Stage Examination’ (MMSE) a clear decline in cogni-
tive function was observed in both groups after the 2nd and 
3rd month post-RT [55].
In a multicenter phase III study on 401 BM patients un-
dergoing WBRT (30Gy/10fr), a significant decline in cognitive 
function was demonstrated based on a test of verbal fluency 
‘Controlled Oral Word Association’ (COWA) in the 4th month 
after RT, which then improved after 15 months post-RT [56]. 
In the Phase II RTOG 0933 study, a verbal learning material 
test was used, i.e. the ‘Hopkins Verbal Learning Test’(HVLT), 
which showed that when the hippocampus is spared in 
BM patients during WBRT, then there is a less severe early 
loss of cognitive function already within the first 4 months 
after the RT, when compared to the pre-treatment 
status [57–59].
Similarly, Chang et al. [57] also observed a smaller loss in 
cognitive function, assessed by HVLT, in learning and short 
term memory in patients with 1–3 BM treated with only 
brain SRT (which facilitated giving a lower radiation dose to 
Figure 2. Neurogenesis of Neural Stem Cells
Figure 1. Lower Neural Stem Cells (NSCs) within the hippocampus
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the hippocampus) as compared to those receiving WBRT. 
A study by Welzel et al. [59] used the AVLT test (Auditory Ver-
bal Learning test) which reported lowered verbal memory 
already 6–8 weeks after completing WBRT in BM patients. In 
a phase III RTOG 0214 clinical study on patients with small 
cell lung cancer (at stage III clinical severity) undergoing 
prophylactic cranial irradiation (PCI), a clear reduction of 
cognitive function was observed at 3 months after brain 
RT when assessed by the MMSE test [60].
Cognitive disorders are also described in post-RT pa-
tients suffering nasopharyngeal carcinoma where, at ap-
proximately 5.5 years after radical RT, they exhibited memory 
and learning dysfunction compared to people of similar age 
but untreated with RT [61]. However, another prospective 
study on patients with nasopharyngeal carcinoma treated 
with RT by using Intensity Modulated Radiation Therapy 
(IMRT) found that, after 18 months post-RT, the test results 
of cognitive function in patients receiving an average dose 
exceeding 36 Gy to the temporal lobe were significantly 
different to those results prior the RT [62].
In summary, applying RT to the area around the brain 
affects cognitive function, which can already become ap-
parent onwards from the second month after RT treatment, 
peaking at about 4 months post-RT [63] (Tab. I).
Cognitive impairment/dysfunction  
following brain RT
Around 90% of BM patients evince some loss of cogni-
tive function even before starting RT whilst in two thirds 
cases there are further losses in cognitive function follow-
ing brain RT [64]. This deficit/deficiency is caused not only 
by the presence of brain cancer itself, but also through the 
progressive effects of extracranial chemotherapy (CHT) or 
adjuvant therapy (including the use of opioids, steroids) as 
well as the presence of comorbidities or the natural dete-
rioration of cognitive functions in elderly patients [65, 66].
A key factor for maintaining normal mental function 
in patients with brain tumour lesions is to prevent their 
progressing in the brain through, for example, the use of 
WBRT [65]. The search for alternatives to preserve or im-
prove cognitive function, (for instance by pharmacological 
means), have not achieved the desired results;  an example 
is afforded by the RTOG 0614 study that used memantine as 
a potential neuro-protecting agent during WBRT and which 
showed no effect on cognitive maintenance [67].
The most commonly reported deficits in cognitive func-
tion after brain RT is memory impairment; often short-term, 
sporadic-deferred [56, 57, 60, 68–70]. Ones less common 
are in remembering/recalling information and in learning 
[57, 68–70]. Those also reported include impaired verbal 
memory, necessary for understanding a read text [56, 59]. 
In addition, impaired fine motor function can be observed 
in the upper limbs and as well as in executive function; 
the higher cognitive processes determining responses to 
new and difficult/challenging situations, such as initiating 
and halting a given response, planning or organising [56]. 
It should be stressed that the deterioration, to any extent, 
of each cognitive function after WBRT leads to a reduced 
QoL [85, 89].
The incidence of neoplastic lesions  
in the hippocampus region
As yet, it is unclear whether the therapeutic gain from 
sparing the hippocampus outweighs the risk of disease pro-
gression at this location. A study by Gondi et al. [71] on 371 
out of 1133 BM patients diagnosed by post contrast MRI T1, 
observed that tumours located in the hippocampus region 
(i.e. the hippocampus including a surrounding 5mm margin) 
account for only up to 3% BM cases and occur in around 
8.6% of patients with brain cancer progression, for which 
there were no metastases present within the hippocampus 
itself. Marsh et al. [72] demonstrated that the majority of 
metastases in the limbic system area occurs in patients with 
multiple BM (> 3). It is worth emphasising that the SVZ, in 
which the NSCs are located represents 2.23% of the whole 
brain volume [73]. It turns out that the risk of metastasis 
in the hippocampal area is approximately 0.5% for oligo-
metastatic disease, i.e. up to 3 BM and approximately 1.5% 
in cases of multiple BM [73].
Metastasis in the SVZ more often occurs in patients 
with small cell lung carcinoma (at 2.7%) compared to pa-
tients with other cancers (0.84%), such as non-small cell 
lung cancer (0.82%) and breast cancer (1.3%) [73]. Prelimi-
nary results from most studies indicate that the therapeutic 
gain achieved when implementing hippocampal sparing 
procedures during brain RT, (i.e. contouring hippocampal 
TK images and with fusing/integrating CT images from MRI 
in planning RT with a small 5 mm margin), outweighs the 
potential risk of local failure [80, 86]. However, in the possible 
event of metastases appearing within the hippocampal area 
then SRT may be considered [71].
Technical means for providing hippocampal 
sparing during brain RT
Sparing the hippocampal region of the brain during 
RT poses a technical challenge in that highly specialised 
radiotherapy techniques need to be applied such as IMRT, 
which provides protective covering/shielding for one or 
both of the centrally located hippocampi according to the 
patient’s clinical requirements (Table II).
Hippocampal sparing in patients  
with primary brain tumours
There is scant research on this issue. Marsch et al. [92, 93] 
have shown that for patients undergoing IMRT in the sur-
roundings of the brain tumour, it is possible to reduce their 
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dose by 56.8% in order to spare the hippocampus and yet 
conform to the IMRT plan as compared to when this organ 
is unprotected i.e. 15.8 Gy vs 36.6 Gy Gy. It should be noted 
that the central location of primary brain tumours often 
prevents shielding both hippocampi, particularly those ones 
immediately adjacent to the hippocampus, or those reach-
ing into the hippocampal area because of tumour swelling 
[74]. Given this situation, many workers suggest sparing 
whichever hippocampus is tumour-free [75, 76].
Hippocampal sparing is especially vital to those children 
where primary brain tumours are diagnosed much more 
frequently than for adults. In children with gliomas of dif-
ferent histological grade, who received RT via tomotherapy, 
56% and 52.1% reductions were achieved respectively in 
the physical or biological average doses of ionizing radia-
tion by Marsh et al. [77] when the hippocampus is treated 
as a critical organ in RT planning, as compared to situations 
where it is not spared.
Table I. Impairment of cognitive function in patients after brain radiotherapy
Study, year RT schedule Number  
of patients
Observation 
time (months) 
Cognitive function test and significant cognitive decline.
Sun et al., 2011 [60] PCI 30Gy/15fr 163 3,6,12 HVLT, MMSE — Significant decrease (p < 0.0001) in immediate HVLT 
response after 3 and 6 months and deferred response decreased 
after 6 months  
Wolfson et al., 2011 [90] PCI 25Gy/10fr 131 6,12 HVLT, COWA — declining HVLT outcomes by 62% after 12 months
PCI 36/18 fr 67 HVLT, COWA — declining HVLT outcomes by 85% after 12 months
PCI 36/ 
2xdaily/24fr
66 HVLT, COWA — declining HVLT outcomes by 89% after 12 months
Chang et al., 2009 [7] WBRT + SRS 
30Gy/12 fr
28 3.5 HVLT — declining deferred memory after 3 months
Welzel et al., 2008 [10] WBRT 40Gy/20fr 16 1.2 AVLT — declining outcomes by 57% after 2 months.
PCI 36Gy/18 fr 13 AVLT — declining outcomes by 44% after 2 months.
Meyers et al., 2004 [14] WBRT 30Gy/10fr 208 12 HVLT, COWA — decreasing cognitive function in both by 48%
Table II. Selected studies where hippocampal sparing was adopted
Study, year Hippocampal dose
Number of 
patients
RT Technique Fractioning D max D av
Gutierrez et al., 2007 [82] 10 WBRT HT 15x2,15 Gy – 5.86 Gy
Gondi et al., 2010 [40] 5 WBRT HT 10x3 Gy 12.8 Gy *5.5 Gy
LINAC 15.3 Gy *7.8 Gy
Hsu et al., 2010 [81] 10 WBRT + SIB LINAC 15x2,15 Gy – 5.23 Gy
Marsh et al., 2010 [91] 11 PCI
HT
15x2 Gy – 12.5 Gy
WBRT 14X 2.5 Gy – 14.3 Gy
Marsh et al., 2011 [92] 12 PBRT HT – – –
van Kesteren et al., 2012 [42] 10 WBRT LINAC 3D 
CRT
12x2.5 Gy 13.5 Gy 6 Gy
Nevelsky et al., 2013 [93] 10 WBRT IMRT 10x3 Gy 14.35 Gy -
Prokic et al., 2013 [83] 10 WBRT + FSRT
Rapid Arc
12x2.5 Gy + 2x 9 Gy 12.33 Gy 7.55 Gy
WBRT + SIB 12x2.5 Gy + 12x4,5 Gy 15.82 Gy 9.8 Gy
Awad et al., 2013 [94] 30 WBRT + SIB Rapid Arct 5–15 fr 32.2 Gy 20.4 Gy
Pokhrel et al., 2015 [95] 10 WBRT VMAT 30Gy/10 fr 11.2 Gy 15.6 Gy
Kothavade et al., 2015 [96] 10 PBRT HT
54 Gy/30 fr
– 20Gy
IMRT – 25 Gy
Oehlke et al., 2015 [97] 20 WBRT + SIB VMAT 30 Gy/12 fr, SIB to 51 Gy – 6.58 Gy
Kim  et al., 2016 [98] 11 WBRT + SIB HT 25–28Gy/10–14 fr, SIB to 48 Gy – 13.65 Gy
Giaj Levra et al., 2016 [99] 10 WBRT + SIB VMAT 20Gy + 40 Gy/5fr 10.5 Gy 7.7 Gy
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Hippocampal sparing in patients irradiated 
electively or those with BM
Blomstrand et al. [78] demonstrated that a variety of RTs 
during WBRT given to children permitted different radiation 
doses to be administered to the hippocampus. They found 
that the average dose given to the hippocampus and SVZ 
was 88.3% of the planned total IMAT dose (i.e. Intensity 
Modulated Arc Therapy), 77.1% of the IMRT and 42.3% for 
IMPT (Intensity Modulated Proton Therapy). Tarnawski et 
al. [79] reported that it was possible to achieve a 45% dose 
reduction when using helical tomotherapy as well as IMRT 
when planning PCI for 10 patients suffering from small cell 
lung cancer, whilst still preserving the therapeutic radiation 
dose to the rest of brain. Similar findings were demonstrated 
by Gondi et al. [80] on five patients when WBRT (30Gy / 10fr) 
was prescribed using helical IMRT or tomotherapy, where 
dose levels were respectively reduced by 87% and 81% for 
the hippocampus. In instances of hippocampal avoidance, 
the therapeutic dose is still, in homogenous fashion, applied 
to the rest of the brain. 
The lowest dose delivered to the hippocampus was 
achieved by Hsu et al. [81] on 10 patients with up to 3 single 
BMs, where SIB-VMAT (Simultaneous Integrated Boost — 
Volumetric-Modulated Arc Therapy) was used post-WBRT, 
so as to increase the radiotherapy dose delivered to the 
BMs. The hippocampus received less than 6 Gy (5.23 Gy 
+/– 0.23 Gy) with respect to conventional fractioning after 
2 Gy, whilst maintaining the planned/proscribed dose to 
the rest of the brain. Likewise, Gutierrez et al. [82] demon-
strated on 10 BM patients undergoing WBRT, that it was 
possible to reduce the hippocampal dose to an average 
total of around 5.8 Gy with single fraction doses being 0.39 
Gy, based on fractioning 2 Gy. A study by Prokic et al. [83] 
reported slightly higher doses, when using VMAT-SIB in BM 
patients also undergoing WBRT, of respectively 7.55 +/– 0.62 
Gy and 6.29 +/– 0.62 Gy at hippocampal margins of 5 an 10 
mm with respect to a 2 Gy fractionation. Additionally, it was 
observed that that the SIB-VMAT technique allowed doses 
delivered to the hippocampus to become reduced even in 
those patients with up to 8 multiple BMs.  
The fractional dose (DF) and total dose (DC) have still 
not yet been unequivocally defined, which would enable 
limbic system function to be retained/continued. Gondi et 
al. [44] determined that the EQD2 (Biologically Equivalent 
Doses in 2 Gy Fractions), of greater than 7.3 Gy delivered to 
more than 40% by volume of both hippocampi results in 
impairment of deferred memory and problems in learning 
and remembering. A study by Gutierrez et al. [81] defined 
an acceptable DF of 0.39 Gy and DC of 5.8 Gy relative to 
the EQD2. Although there is no clinical data on any aver-
age dose suitable to the hippocampus, it is assumed that 
a DC exceeding 15.8 Gy – 24.9 Gy is sufficient for retaining 
cognitive function [84].
Based on the RTOG 0933 study, preliminary recommen-
dations were proposed for dose tolerances to the hippocam-
pus in BM patients which could deliver a survival longer than 
6 months when using WBRT, i.e. the DC should not exceed 
7.8 Gy and the dose to the entire hippocampus should not 
exceed 10 Gy, whilst the maximum dose should not rise 
above 15.3 Gy [85]. The study suggests the contouring of 
critical structures responsible for neurogenesis, i.e. the SVZ 
with a 5 mm margin of surrounding tissue. A contour atlas 
of the hippocampus can be found on the RTOG website [86].
It is finally worth mentioning about the search for objec-
tive methods for assessing cognitive impairment in patients 
with post-cerebral RT. In a proton MR spectroscopy study on 
patients that had undergone WBRT 4 months earlier, reduced 
concentrations of N-acetylaspartate were noted; this being 
a metabolite of nerve tissue from the hippocampal region 
[87]. Another study using MR spectroscopy found sub-acute 
radiation damage to nerve tissue after a month post-WBRT 
[88]. It seems likely that such studies will in the future provide 
a more accurate assessment of cognitive impairment in pa-
tients after brain RT as opposed to those subjective methods 
for assessing the hippocampus, (i.e. the cognitive studies). 
Summary and conclusions
RT in patients with primary and metastatic brain tu-
mours is still an important treatment, but it remains associ-
ated with certain cognitive dysfunctions. The hippocampus 
is one of the brain structures that are acutely sensitive to 
ionizing radiation, particularly the so-called active neu-
rogenesis regions in which NSCs proliferate. Indeed, NSC 
function has been proved to assure that the limbic system 
operates normally; this being primarily responsible for cog-
nitive function.
Radiation damage to the hippocampus may play a key 
role for decreasing patient QoL after brain RT through cog-
nitive impairment. Shortcomings in these functions com-
monly include problems with learning, memory, (both short-
term and deferred) and processing of information previously 
stored. A series of studies using subjective methods for 
assessing patient’s cognitive functions, post-RT, by means 
of psychological tests such as ‘mini-mental’, AVLT, HVLT or 
COWA demonstrated a distinct loss of cognitive function 
already apparent at about 2–3 months after treatment. An 
objective test or marker capable of detecting damage to 
hippocampal structures is however still being sought for. 
Further clinical trials are required, which would allow the 
best RT to be selected, thus allowing the hippocampus to be 
protected in a variety of specific clinical situations. It is also 
important to define patient groups who could tangibly ben-
efit from hippocampal sparing when undergoing brain RT.
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